Sometimes a company just knows how to read the room. While the broader market was having a forgettable Tuesday with the Nasdaq down 0.19% and the S&P 500 falling 0.20%, Revvity, Inc. (RVTY) decided to buck the trend entirely. The life sciences and diagnostics company released preliminary fourth-quarter numbers that had investors feeling pretty good about things.

The stock jumped 6.02% to close at $110.14, which is the kind of move you get when you deliver results that actually beat expectations. Revvity announced it will release official fourth-quarter and full-year 2025 financial results on February 2, 2026, but the preliminary peek was enough to get traders excited.

Revenue Growth Beats the Street

Here's what caught everyone's attention: Revvity posted preliminary reported revenue growth of approximately 6% for the fourth quarter, bringing in around $772 million. Analysts were expecting $760.6 million, so that's a nice beat. For the full year, revenue is projected to hit approximately $2.855 billion, reflecting roughly 4% year-over-year growth compared to the consensus estimate of $2.84 billion.

Even better, the company expects its 2025 adjusted earnings per share to exceed the upper end of its previous guidance range of $4.90 to $5.00. When you're beating your own optimistic projections, that's usually a good sign.

The 2026 Outlook

Looking forward, Revvity is projecting organic growth of 2%-3% for 2026, along with high single-digit growth in adjusted earnings per share. The company expects existing end market trends to continue into the new year and believes it's on track to achieve adjusted operating margins of around 28%.

Those aren't explosive growth numbers, but they're solid and steady, which is exactly what you want from a life sciences company navigating a somewhat uncertain economic environment.

Technical Picture Shows Momentum

From a technical perspective, Revvity is showing some interesting strength. The stock is currently trading 11.2% above its 20-day simple moving average and 17.5% above its 100-day simple moving average, which demonstrates solid short-term momentum. Despite shares being down 10.14% over the past 12 months, they're positioned much closer to their 52-week highs than lows, suggesting a potential rebound is underway.

The RSI sits at 59.86, which is neutral territory, meaning the stock isn't overbought or oversold. Meanwhile, the MACD is above its signal line, pointing to bullish momentum. It's a mixed picture that suggests traders should keep an eye out for potential breakout opportunities.

Key technical levels to watch: resistance at $117.00 and support at $89.50.

What the Analysts Think

Wall Street seems pretty comfortable with Revvity's story. The stock carries a Buy rating with an average price target of $120.24, which represents about 9% upside from current levels. Recent analyst activity includes:

• Barclays: Overweight rating with a raised target of $115.00
• Wells Fargo: Equal-Weight rating with a raised target of $107.00
• Goldman Sachs: Initiated coverage with a Neutral rating and $105.00 target

Here's the interesting part: while the stock trades at a premium P/E multiple, analysts seem to think the 8% expected earnings growth justifies the valuation. That's why you're seeing that 9% upside to analyst targets despite the already elevated multiple.

Market Position Scorecard

Looking at Revvity's broader market positioning reveals some interesting contrasts:

• Momentum: Weak (Score: 18.91/100) — Despite today's pop, the stock has been underperforming the broader market over longer timeframes.
• Quality: Neutral (Score: 39.51/100) — The balance sheet remains stable, which is reassuring.
• Value: Weak (Score: 16.37/100) — The stock is trading at a steep premium relative to peers, which explains why some analysts remain cautious.

ETF Exposure

If you're looking for ETF exposure to Revvity, the First Trust Indxx Medical Devices ETF (MDEV) holds a 2.18% weight in the stock.

All in all, Revvity delivered exactly what the market wanted to see: results that beat expectations, guidance that came in ahead of forecasts, and a 2026 outlook that suggests the momentum isn't about to fade. In a market environment where good news has been hard to come by, that's enough to earn you a 6% gain for the day.